Compare MYGN & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | IHRT |
|---|---|---|
| Founded | 1991 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 623.2M |
| IPO Year | 1995 | 2019 |
| Metric | MYGN | IHRT |
|---|---|---|
| Price | $5.91 | $3.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $11.82 | $4.33 |
| AVG Volume (30 Days) | ★ 933.3K | 699.5K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $825,300,000.00 | ★ $3,856,033,000.00 |
| Revenue This Year | $0.03 | $1.96 |
| Revenue Next Year | $5.38 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.21 | ★ 1.39 |
| 52 Week Low | $3.76 | $0.95 |
| 52 Week High | $15.47 | $5.44 |
| Indicator | MYGN | IHRT |
|---|---|---|
| Relative Strength Index (RSI) | 32.96 | 40.89 |
| Support Level | $5.81 | $3.59 |
| Resistance Level | $6.20 | $3.96 |
| Average True Range (ATR) | 0.31 | 0.19 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 7.09 | 24.07 |
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.